SG175133A1 - Methods of treating edema related to ischemia-reperfusion - Google Patents

Methods of treating edema related to ischemia-reperfusion Download PDF

Info

Publication number
SG175133A1
SG175133A1 SG2011073475A SG2011073475A SG175133A1 SG 175133 A1 SG175133 A1 SG 175133A1 SG 2011073475 A SG2011073475 A SG 2011073475A SG 2011073475 A SG2011073475 A SG 2011073475A SG 175133 A1 SG175133 A1 SG 175133A1
Authority
SG
Singapore
Prior art keywords
tissue
compound
ischemia
transplant
reperfusion
Prior art date
Application number
SG2011073475A
Other languages
English (en)
Inventor
Thomas Michael Egan
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of SG175133A1 publication Critical patent/SG175133A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10Preservation of living parts
    • A01N1/12Chemical aspects of preservation
    • A01N1/122Preservation or perfusion media
    • A01N1/126Physiologically active agents, e.g. antioxidants or nutrients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
SG2011073475A 2009-04-09 2010-04-09 Methods of treating edema related to ischemia-reperfusion SG175133A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16808909P 2009-04-09 2009-04-09
PCT/US2010/030556 WO2010118334A1 (en) 2009-04-09 2010-04-09 Methods of treating edema related to ischemia-reperfusion

Publications (1)

Publication Number Publication Date
SG175133A1 true SG175133A1 (en) 2011-12-29

Family

ID=42936599

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011073475A SG175133A1 (en) 2009-04-09 2010-04-09 Methods of treating edema related to ischemia-reperfusion

Country Status (14)

Country Link
US (1) US20120064044A1 (enExample)
EP (1) EP2416651A4 (enExample)
JP (1) JP2012523432A (enExample)
KR (1) KR20120005025A (enExample)
CN (1) CN102458113A (enExample)
AU (1) AU2010233151A1 (enExample)
BR (1) BRPI1010516A2 (enExample)
CA (1) CA2757998A1 (enExample)
EA (1) EA201101349A1 (enExample)
IL (1) IL215604A0 (enExample)
MX (1) MX2011010616A (enExample)
SG (1) SG175133A1 (enExample)
WO (1) WO2010118334A1 (enExample)
ZA (1) ZA201107815B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5562939B2 (ja) * 2008-04-09 2014-07-30 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル アクチン細胞骨格再編成及び細胞間ギャップ形成調節の方法
CN103492572A (zh) * 2011-03-03 2014-01-01 夸克医药公司 用于治疗肺疾病和损伤的组合物和方法
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
JP7330893B2 (ja) 2017-03-10 2023-08-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
WO2019090203A1 (en) 2017-11-03 2019-05-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
EP3752182B1 (en) 2018-02-12 2024-05-15 Inimmune Corporation Toll-like receptor ligands
WO2019246264A1 (en) 2018-06-20 2019-12-26 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
JP2023501568A (ja) * 2019-11-13 2023-01-18 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 肝虚血再灌流障害におけるヘパラン硫酸(hs)オリゴ糖の効果

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05139992A (ja) * 1991-11-13 1993-06-08 Ajinomoto Co Inc ヒトadfを含有する臓器保護剤
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7960522B2 (en) * 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
JPWO2004085396A1 (ja) * 2003-03-26 2006-06-29 三菱ウェルファーマ株式会社 虚血再灌流障害の予防または治療剤、臓器保存剤およびスクリーニング方法
US7928132B2 (en) * 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
EP2170366B1 (en) * 2007-08-03 2013-11-06 Opsona Therapeutics Limited Use of tlr-2 antagonists for treatment of reperfusion injury and tissue damage
JP5562939B2 (ja) * 2008-04-09 2014-07-30 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル アクチン細胞骨格再編成及び細胞間ギャップ形成調節の方法

Also Published As

Publication number Publication date
EP2416651A1 (en) 2012-02-15
JP2012523432A (ja) 2012-10-04
US20120064044A1 (en) 2012-03-15
WO2010118334A1 (en) 2010-10-14
MX2011010616A (es) 2012-03-14
CN102458113A (zh) 2012-05-16
KR20120005025A (ko) 2012-01-13
ZA201107815B (en) 2013-04-24
CA2757998A1 (en) 2010-10-14
EP2416651A4 (en) 2014-03-26
EA201101349A1 (ru) 2012-05-30
BRPI1010516A2 (pt) 2015-08-25
IL215604A0 (en) 2011-12-29
AU2010233151A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
US20120064044A1 (en) Methods of treating edema related to ischemia-reperfusion
Hou et al. Sphingosine 1-phosphate receptor 2 signaling suppresses macrophage phagocytosis and impairs host defense against sepsis
CA2659542C (en) Methods and compositions for inhibiting angiogenesis
Li et al. Bone marrow‐derived mesenchymal stem cells enhance autophagy via PI 3K/AKT signalling to reduce the severity of ischaemia/reperfusion‐induced lung injury
US20230277580A1 (en) Cell protective methods and compositions
US8809303B2 (en) Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
JP2020536048A (ja) 発毛を調節するための組成物及び方法
Hossain et al. Experimental study of the effect of intraportal prostaglandin E1 on hepatic blood flow during reperfusion after ischaemia and hepatectomy
CN115518158B (zh) mTOR抑制剂体外诱导树突状细胞及其应用
JP2022083279A (ja) 腎臓保護用の組成物
US20240423969A1 (en) Synergistic drug combinations to treat cancer
Choi Effect of Remote Ischemic Conditioning on Lipopolysaccharide-induced Pulmonary Inflammation
Walkup et al. Endothelial cell impact on adult derived hepatic progenitor cells
Chen et al. Cyclosporin a increased malondialdehyde formation in EBV-infected human B cells is inhibited by Vitamin E
Watts III et al. Monophosphoryl lipid A prevents impairment of medullary thick ascending LIMB 4 HCO3-absorption and improves plasma HCO3-concentration in septic mice 5
CN103989701A (zh) 聚乙二醇4000或聚乙二醇6000在制备预防或治疗水母毒素心脏毒性药物中的应用